Selected research
Industry Research
Tuberculosis Drugs Industry Research Report 2026
Market perspective
The global Tuberculosis Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Tuberculosis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Tuberculosis Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Tuberculosis Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Tuberculosis Drugs include Abbott, Teva Pharmaceutical Industries Ltd, Sanofi, Johnson & Johnson, Novartis AG, Eli Lilly and Company, Pfizer Inc, AstraZeneca Plc and Viatris Inc. (Mylan N.V.), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Tuberculosis Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Tuberculosis Drugs Market by Company
Abbott
Teva Pharmaceutical Industries Ltd
Sanofi
Johnson & Johnson
Novartis AG
Eli Lilly and Company
Pfizer Inc
AstraZeneca Plc
Viatris Inc. (Mylan N.V.)
Sun Pharmaceutical Industries Ltd.
Otsuka Pharmaceutical
Macleods Pharmaceuticals Ltd.
Lupin Laboratories Ltd
FRESENIUS SE & Co. KGaA (Fresenius Kabi)
Cipla Ltd
Cadila Pharmaceuticals
ANI Pharmaceuticals, Inc
Alkem Laboratories Ltd
Tuberculosis Drugs Segment by Type
First Line Drugs Therapy
Combination Drugs Therapy
Second Line Drugs Therapy
Tuberculosis Drugs Segment by Application
Hospital
Private Clinic
Others
Tuberculosis Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tuberculosis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Tuberculosis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tuberculosis Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Tuberculosis Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Tuberculosis Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Tuberculosis Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- First Line Drugs Therapy
- Combination Drugs Therapy
- Second Line Drugs Therapy
Applications
- Hospital
- Private Clinic
- Others
Companies covered
- Abbott
- Teva Pharmaceutical Industries Ltd
- Sanofi
- Johnson & Johnson
- Novartis AG
- Eli Lilly and Company
- Pfizer Inc
- AstraZeneca Plc
- Viatris Inc. (Mylan N.V.)
- Sun Pharmaceutical Industries Ltd.
- Otsuka Pharmaceutical
- Macleods Pharmaceuticals Ltd.
- Lupin Laboratories Ltd
- FRESENIUS SE & Co. KGaA (Fresenius Kabi)
- Cipla Ltd
- Cadila Pharmaceuticals
- ANI Pharmaceuticals, Inc
- Alkem Laboratories Ltd
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Tuberculosis Drugs Market Size (2021-2032)
- 2.2.2 Global Tuberculosis Drugs Sales (2021-2032)
- 2.2.3 Global Tuberculosis Drugs Market Average Price (2021-2032)
- 2.3 Tuberculosis Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 First Line Drugs Therapy
- 2.3.3 Combination Drugs Therapy
- 2.3.4 Second Line Drugs Therapy
- 2.4 Tuberculosis Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Private Clinic
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Tuberculosis Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Tuberculosis Drugs Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Tuberculosis Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Tuberculosis Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Tuberculosis Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Tuberculosis Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Tuberculosis Drugs, Product Type & Application
- 3.8 Global Manufacturers of Tuberculosis Drugs, Established Date
- 3.9 Global Tuberculosis Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Abbott
- 4.1.1 Abbott Company Information
- 4.1.2 Abbott Business Overview
- 4.1.3 Abbott Tuberculosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Abbott Tuberculosis Drugs Product Portfolio
- 4.1.5 Abbott Recent Developments
- 4.2 Teva Pharmaceutical Industries Ltd
- 4.2.1 Teva Pharmaceutical Industries Ltd Company Information
- 4.2.2 Teva Pharmaceutical Industries Ltd Business Overview
- 4.2.3 Teva Pharmaceutical Industries Ltd Tuberculosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Teva Pharmaceutical Industries Ltd Tuberculosis Drugs Product Portfolio
- 4.2.5 Teva Pharmaceutical Industries Ltd Recent Developments
- 4.3 Sanofi
- 4.3.1 Sanofi Company Information
- 4.3.2 Sanofi Business Overview
- 4.3.3 Sanofi Tuberculosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Sanofi Tuberculosis Drugs Product Portfolio
- 4.3.5 Sanofi Recent Developments
- 4.4 Johnson & Johnson
- 4.4.1 Johnson & Johnson Company Information
- 4.4.2 Johnson & Johnson Business Overview
- 4.4.3 Johnson & Johnson Tuberculosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Johnson & Johnson Tuberculosis Drugs Product Portfolio
- 4.4.5 Johnson & Johnson Recent Developments
- 4.5 Novartis AG
- 4.5.1 Novartis AG Company Information
- 4.5.2 Novartis AG Business Overview
- 4.5.3 Novartis AG Tuberculosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Novartis AG Tuberculosis Drugs Product Portfolio
- 4.5.5 Novartis AG Recent Developments
- 4.6 Eli Lilly and Company
- 4.6.1 Eli Lilly and Company Company Information
- 4.6.2 Eli Lilly and Company Business Overview
- 4.6.3 Eli Lilly and Company Tuberculosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Eli Lilly and Company Tuberculosis Drugs Product Portfolio
- 4.6.5 Eli Lilly and Company Recent Developments
- 4.7 Pfizer Inc
- 4.7.1 Pfizer Inc Company Information
- 4.7.2 Pfizer Inc Business Overview
- 4.7.3 Pfizer Inc Tuberculosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Pfizer Inc Tuberculosis Drugs Product Portfolio
- 4.7.5 Pfizer Inc Recent Developments
- 4.8 AstraZeneca Plc
- 4.8.1 AstraZeneca Plc Company Information
- 4.8.2 AstraZeneca Plc Business Overview
- 4.8.3 AstraZeneca Plc Tuberculosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 AstraZeneca Plc Tuberculosis Drugs Product Portfolio
- 4.8.5 AstraZeneca Plc Recent Developments
- 4.9 Viatris Inc. (Mylan N.V.)
- 4.9.1 Viatris Inc. (Mylan N.V.) Company Information
- 4.9.2 Viatris Inc. (Mylan N.V.) Business Overview
- 4.9.3 Viatris Inc. (Mylan N.V.) Tuberculosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Viatris Inc. (Mylan N.V.) Tuberculosis Drugs Product Portfolio
- 4.9.5 Viatris Inc. (Mylan N.V.) Recent Developments
- 4.10 Sun Pharmaceutical Industries Ltd.
- 4.10.1 Sun Pharmaceutical Industries Ltd. Company Information
- 4.10.2 Sun Pharmaceutical Industries Ltd. Business Overview
- 4.10.3 Sun Pharmaceutical Industries Ltd. Tuberculosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Sun Pharmaceutical Industries Ltd. Tuberculosis Drugs Product Portfolio
- 4.10.5 Sun Pharmaceutical Industries Ltd. Recent Developments
- 4.11 Otsuka Pharmaceutical
- 4.11.1 Otsuka Pharmaceutical Company Information
- 4.11.2 Otsuka Pharmaceutical Business Overview
- 4.11.3 Otsuka Pharmaceutical Tuberculosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Otsuka Pharmaceutical Tuberculosis Drugs Product Portfolio
- 4.11.5 Otsuka Pharmaceutical Recent Developments
- 4.12 Macleods Pharmaceuticals Ltd.
- 4.12.1 Macleods Pharmaceuticals Ltd. Company Information
- 4.12.2 Macleods Pharmaceuticals Ltd. Business Overview
- 4.12.3 Macleods Pharmaceuticals Ltd. Tuberculosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Macleods Pharmaceuticals Ltd. Tuberculosis Drugs Product Portfolio
- 4.12.5 Macleods Pharmaceuticals Ltd. Recent Developments
- 4.13 Lupin Laboratories Ltd
- 4.13.1 Lupin Laboratories Ltd Company Information
- 4.13.2 Lupin Laboratories Ltd Business Overview
- 4.13.3 Lupin Laboratories Ltd Tuberculosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Lupin Laboratories Ltd Tuberculosis Drugs Product Portfolio
- 4.13.5 Lupin Laboratories Ltd Recent Developments
- 4.14 FRESENIUS SE & Co. KGaA (Fresenius Kabi)
- 4.14.1 FRESENIUS SE & Co. KGaA (Fresenius Kabi) Company Information
- 4.14.2 FRESENIUS SE & Co. KGaA (Fresenius Kabi) Business Overview
- 4.14.3 FRESENIUS SE & Co. KGaA (Fresenius Kabi) Tuberculosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 FRESENIUS SE & Co. KGaA (Fresenius Kabi) Tuberculosis Drugs Product Portfolio
- 4.14.5 FRESENIUS SE & Co. KGaA (Fresenius Kabi) Recent Developments
- 4.15 Cipla Ltd
- 4.15.1 Cipla Ltd Company Information
- 4.15.2 Cipla Ltd Business Overview
- 4.15.3 Cipla Ltd Tuberculosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Cipla Ltd Tuberculosis Drugs Product Portfolio
- 4.15.5 Cipla Ltd Recent Developments
- 4.16 Cadila Pharmaceuticals
- 4.16.1 Cadila Pharmaceuticals Company Information
- 4.16.2 Cadila Pharmaceuticals Business Overview
- 4.16.3 Cadila Pharmaceuticals Tuberculosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Cadila Pharmaceuticals Tuberculosis Drugs Product Portfolio
- 4.16.5 Cadila Pharmaceuticals Recent Developments
- 4.17 ANI Pharmaceuticals, Inc
- 4.17.1 ANI Pharmaceuticals, Inc Company Information
- 4.17.2 ANI Pharmaceuticals, Inc Business Overview
- 4.17.3 ANI Pharmaceuticals, Inc Tuberculosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 ANI Pharmaceuticals, Inc Tuberculosis Drugs Product Portfolio
- 4.17.5 ANI Pharmaceuticals, Inc Recent Developments
- 4.18 Alkem Laboratories Ltd
- 4.18.1 Alkem Laboratories Ltd Company Information
- 4.18.2 Alkem Laboratories Ltd Business Overview
- 4.18.3 Alkem Laboratories Ltd Tuberculosis Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.18.4 Alkem Laboratories Ltd Tuberculosis Drugs Product Portfolio
- 4.18.5 Alkem Laboratories Ltd Recent Developments
5 Global Tuberculosis Drugs Market Scenario by Region
- 5.1 Global Tuberculosis Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Tuberculosis Drugs Sales by Region: 2021-2032
- 5.2.1 Global Tuberculosis Drugs Sales by Region: 2021-2026
- 5.2.2 Global Tuberculosis Drugs Sales by Region: 2027-2032
- 5.3 Global Tuberculosis Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Tuberculosis Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Tuberculosis Drugs Revenue by Region: 2027-2032
- 5.4 North America Tuberculosis Drugs Market Facts & Figures by Country
- 5.4.1 North America Tuberculosis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Tuberculosis Drugs Sales by Country (2021-2032)
- 5.4.3 North America Tuberculosis Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Tuberculosis Drugs Market Facts & Figures by Country
- 5.5.1 Europe Tuberculosis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Tuberculosis Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Tuberculosis Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Tuberculosis Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Tuberculosis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Tuberculosis Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Tuberculosis Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Tuberculosis Drugs Market Facts & Figures by Country
- 5.7.1 South America Tuberculosis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Tuberculosis Drugs Sales by Country (2021-2032)
- 5.7.3 South America Tuberculosis Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Tuberculosis Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Tuberculosis Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Tuberculosis Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Tuberculosis Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Tuberculosis Drugs Sales by Type (2021-2032)
- 6.1.1 Global Tuberculosis Drugs Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Tuberculosis Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Tuberculosis Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Tuberculosis Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Tuberculosis Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Tuberculosis Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Tuberculosis Drugs Sales by Application (2021-2032)
- 7.1.1 Global Tuberculosis Drugs Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Tuberculosis Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Tuberculosis Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Tuberculosis Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Tuberculosis Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Tuberculosis Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Tuberculosis Drugs Value Chain Analysis
- 8.1.1 Tuberculosis Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Tuberculosis Drugs Production Mode & Process
- 8.2 Tuberculosis Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Tuberculosis Drugs Distributors
- 8.2.3 Tuberculosis Drugs Customers
9 Global Tuberculosis Drugs Analyzing Market Dynamics
- 9.1 Tuberculosis Drugs Industry Trends
- 9.2 Tuberculosis Drugs Industry Drivers
- 9.3 Tuberculosis Drugs Industry Opportunities and Challenges
- 9.4 Tuberculosis Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst